Related Experiment Video
Updated: Jun 24, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.7K
The effect of inhaler prescription on the development of lung cancer in COPD: a nationwide population-based study
Ji Eun Park1, Eunyoung Lee2, Dave Singh3
1Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Worldcup-ro 164, Suwon, Gyeonggi-do, 16499, Republic of Korea.
Respiratory Research
|May 31, 2024
Summary
Inhaled corticosteroid inhaler use in COPD patients did not significantly impact lung cancer development. Instead, diffuse interstitial lung disease, higher comorbidity scores, and frequent hospitalizations were linked to increased lung cancer risk.
Area of Science:
- Pulmonology
- Oncology
- Epidemiology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is a known risk factor for lung cancer.
- The potential protective effect of inhaled corticosteroids (ICS) against lung cancer in COPD patients remains debated.
- This study examines lung cancer development in relation to inhaler prescriptions and comorbidities within a COPD cohort.
Purpose of the Study:
- To investigate the association between different inhaler prescriptions and the incidence of lung cancer in COPD patients.
- To identify comorbidities and patient factors independently associated with lung cancer development in COPD.
Main Methods:
- A retrospective cohort study utilized data from the Korean Health Insurance Review and Assessment Service.
- Included were COPD patients aged 40 years or older with new inhaler prescriptions, excluding those with prior cancer history or inhaler switches.
- Lung cancer development was tracked from the index date to December 31, 2020.
Main Results:
- Among 63,442 eligible COPD patients, the most common inhaler groups were LAMA/LABA (62.4%) and ICS/LABA (35.8%).
- Multivariate analysis revealed no significant association between inhaler prescription type and lung cancer development.
- Independent predictors for lung cancer included diffuse interstitial lung disease (DILD), higher Charlson Comorbidity Index, and multiple hospitalizations, alongside older age and male sex.
Conclusions:
- Lung cancer development in COPD patients is not independently linked to the type of inhaler prescribed.
- Coexisting diffuse interstitial lung disease (DILD), a higher Charlson Comorbidity Index score, and frequent hospitalizations are significant risk factors for lung cancer in COPD.
- These findings highlight the importance of managing comorbidities and specific lung conditions in COPD patients at risk for lung cancer.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
01:20COPD: Pathogenesis and Clinical Features
259
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
259
01:23Inhaled Medications
252
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
252
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K